NEW YORK (GenomeWeb News) – Cancer genetic testing firm NeoGenomics today said that its revenues for the first quarter bounced 3 percent year over year.

Revenues for the three months ending March 31 totaled $15.7 million, compared to $15.2 million a year ago, as the number of requisitions in the quarter increased to 20,604 from 16,934 a year ago, and the number of tests performed climbed to 32,088 from 26,932.

Net income was down, however, to $3,000, or breakeven on a per-share basis, compared to a profit of $603,000, or $.01 per share, a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.